UNIVERSAL CORP quarterly report, Q1 FY2021

Business context and reporting period

This filing covers Universal Corporation’s quarter ended June 30, 2021, the first quarter of fiscal 2022, with comparison to the quarter ended June 30, 2020. The request metadata says “2020 Q1,” but the filing itself is for 2021 Q1. Universal supplies leaf tobacco globally and plant-based ingredients for food and beverage markets. Results are seasonal and may not indicate full-year performance.

Financial results

Revenue rose 11%, principally reflecting the October 2020 Silva acquisition; tobacco revenue declined modestly. Tobacco sales were $270.3 million versus $275.1 million, while ingredient sales increased to $51.9 million from $16.4 million. Adjusted operating income, a non-GAAP measure, was $12.6 million versus $4.4 million; adjusted diluted EPS was $0.30 versus $0.02. These adjusted comparisons exclude specified restructuring, impairment, acquisition-related, tax, and other items.

Tobacco Operations revenue was $293.8 million, down 2%; segment operating income increased to $8.9 million from $5.0 million, supported by African carryover shipments, product mix, and increased customer supply-chain services. Ingredients Operations revenue was $56.2 million versus $17.4 million, and segment operating income was $4.3 million versus a $0.7 million loss, reflecting Silva and strong volumes in human and pet food categories.

Cash flow, balance sheet, and liquidity

The consolidated cash flow statement reports operating cash use of $126.9 million, compared with $0.05 million provided a year earlier, largely reflecting seasonal working-capital investment. The MD&A separately describes operating cash use of $120.9 million; the filing text does not explain this difference clearly. Capital expenditures were $14.4 million versus $8.4 million. Cash, cash equivalents, and restricted cash ended the quarter at $90.7 million, including $84.7 million of cash and cash equivalents.

At June 30, 2021, current assets were $1.60 billion and current liabilities were $353.2 million. Notes payable and overdrafts were $153.3 million; long-term debt was $518.3 million. Net debt as a percentage of net capitalization was approximately 31%, versus 23% a year earlier and 25% at March 31, 2021. The company reported compliance with debt covenants, $405 million available under its committed revolving facility, and approximately $138 million of unused uncommitted credit lines. No long-term debt matures until fiscal 2024. Management said available liquidity is expected to cover requirements for at least the next 12 months.

Material changes, outlook, and risks

• The Silva acquisition expanded ingredients operations and contributed to higher revenue, assets, and debt. Preliminary purchase accounting remained subject to finalization, expected in fiscal 2022’s second quarter.
• Restructuring and impairment costs were $2.0 million: $1.5 million for tobacco-operation restructuring in Africa and $0.5 million related to the CIFI wind-down. CIFI assets had previously incurred substantial impairment charges.
• Quarterly reported earnings were affected by comparison items: the prior-year period included a $4.2 million reversal of FruitSmart contingent consideration and a $4.4 million tax benefit; it also included $1.8 million of interest expense tied to an uncertain tax matter.
• Management said both segments were performing according to plan and reiterated its goal for ingredients to represent 10%–20% of company “results” in fiscal 2022; the filing does not define that measure more precisely. Expected capital spending over the next 12 months is $35–$45 million. No specific earnings or revenue guidance was provided.
• COVID-19 impacts remained uncertain. Management noted worldwide vessel and container constraints that could affect shipment timing and quarterly comparisons, though it had not experienced a material supply-chain impact to date.
• Brazil VAT assessments remained contested: approximately $9 million for Santa Catarina and $3 million for Paraná, with no liability recorded because management considered a loss not probable. Resolution may take a long time. Other litigation and tax matters were not expected to materially affect financial position, though an adverse outcome could materially affect a particular period’s results.
• Other exposures include foreign-exchange and interest-rate changes, seasonal crop financing and inventory, reliance on a limited number of large customers, and integration and execution risks for acquisitions. Variable-rate debt was approximately $303 million; a 1% short-term rate change was estimated to affect annual interest expense by about $3.0 million, partly offset by customer charges.

Important facts for investors to verify

• Confirm the intended reporting period: this is the quarter ended June 30, 2021, not 2020 Q1.
• Reconcile the MD&A’s $120.9 million operating-cash-use figure with the cash flow statement’s $126.9 million.
• Track seasonal cash use, tobacco inventory commitments, and the effect of shipping delays on sales timing and working capital.
• Assess Silva’s ongoing contribution and the final purchase-price allocation, alongside CIFI wind-down costs.
• Monitor debt, variable-rate exposure, revolving-facility availability, and the contested Brazil VAT assessments.